At a glance
ClinicalIndex Comparison RecordN/AActive· 51 enrolled
Drug / intervention
Aortic valve replacementdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of ACURATE Neo 2 Valve in Patients With Symptomatic Aortic Valve Stenosis
In Brief
An observational study evaluating Aortic valve replacement for Severe Aortic Valve Stenosis. Active but no longer recruiting, targeting 51 participants across 7 sites in 3 countries.
Detailed Summary
The objective of this study is to evaluate the ACURATE Neo2 in the Middle East population with severe, symptomatic aortic stenosis.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Aortic Valve Stenosis
CountriesEgypt, Lebanon, Saudi Arabia
CollaboratorsEuropean Cardiovascular Research Center
Timeline
N/AActiveOverdue
202420252026
First PostedMay 2023
Enrollment StartMar 2024
Primary CompletionApr 2026
Study CompletionMay 2026
TodayJul 2026
First PostedMay 8, 2023
Enrollment StartMar 6, 2024
Primary CompletionApr 1, 2026
Study CompletionMay 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 3.1 years ago
Interventions
Aortic valve replacementdevice
Trans Aortic Valve Replacement (TAVI)